Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Sep 21;7(4):338-341.
doi: 10.1007/s13340-016-0288-5. eCollection 2016 Dec.

Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule

Toyoshi Inoguchi  1 , Noriyuki Sonoda  2 , Yasutaka Maeda  2
Affiliations
Editorial

Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule

Toyoshi Inoguchi et al. Diabetol Int. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

This article does not report any original studies with human or animal subjects that were performed by any of the authors.T. Inoguchi received speaker honoraria from Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Sanofi K.K., Astellas Pharma Inc., Kowa Pharmaceutical Co. Ltd., Novartis Pharma K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Co. Ltd., Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd. N. Sonoda received speaker honoraria from Takeda Pharmaceutical Co. Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation. T. Inoguchi received scholarship grants from Dainippon Sumitomo Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Co. Ltd. Y. Maeda has no conflict of interest.

Figures

Fig. 1
Fig. 1
The possible protective role of bilirubin on oxidative stress- and chronic inflammation-associated multiple organ dysfunction in metabolic syndrome and diabetes. FFA free fatty acid, NAFLD non-alcoholic fatty liver disease, CKD chronic kidney disease
See this image and copyright information in PMC

References

    1. Inoguchi T, Sasaki S, Kobayashi K, et al. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA. 2007;298:1398–1400. doi: 10.1001/jama.298.12.1398-b. - DOI - PubMed
    1. Fukui M, Tanaka M, Shiraishi E, et al. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int. 2008;74(1197–20):1. - PubMed
    1. Yasuda M, Kiyohara Y, Wang JJ, et al. High serum bilirubin levels and diabetic retinopathy: the Hisayama Study. Opthalmology. 2011;118:1423–1428. - PubMed
    1. Han SS, Na KY, Chin HJ, et al. High serum bilirubin is associated wuth the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med. 2010;221:133–140. doi: 10.1620/tjem.221.133. - DOI - PubMed
    1. Riphagen IJ, Deetman PE, Bakker SJL, et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENNAL with independent replication in IDNT. Diabetes. 2014;63:2845–2853. doi: 10.2337/db13-1652. - DOI - PubMed

Publication types

LinkOut - more resources